ALAUNOS THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.32 USD | +13.79% |
|
+17.86% | +24.47% |
| Apr. 01 | Alaunos Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Mar. 05 | North American Morning Briefing : S&P 500 Futures -2- | DJ |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 847.1 | 536.6 | 234 | 155.4 | 16.98 | 21.14 |
| Enterprise Value (EV) 1 | 847.1 | 421.5 | 234 | 155.4 | 16.98 | 21.14 |
| P/E ratio | -6.74 x | -6.63 x | -2.95 x | -3.82 x | -0.48 x | -2.2 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | - | - | 588 x | 53.2 x | 3,396 x | - |
| EV / Revenue | - | - | 588 x | 53.2 x | 3,396 x | - |
| EV / EBITDA | -14,801,120 x | -6,772,437 x | - | - | - | - |
| EV / FCF | - | -8,034,024 x | -3,610,877 x | - | - | - |
| FCF Yield | - | -0% | -0% | - | - | - |
| Price to Book | - | - | - | - | - | - |
| Nbr of stocks (in thousands) | 11,964 | 14,196 | 14,309 | 15,965 | 16,013 | 16,012 |
| Reference price 2 | 70.80 | 37.80 | 16.35 | 9.736 | 1.060 | 1.320 |
| Announcement Date | 3/2/20 | 2/25/21 | 3/30/22 | 3/7/23 | 4/1/24 | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Net sales 1 | - | - | 0.398 | 2.922 | 0.005 | - |
| EBITDA | -57.23 | -79.23 | - | - | - | - |
| EBIT 1 | -57.86 | -80.36 | -73.31 | -35.1 | -34.27 | -8.305 |
| Operating Margin | - | - | -18,419.35% | -1,201.4% | -685,340% | - |
| Earnings before Tax (EBT) 1 | -117.8 | -79.98 | -78.75 | -37.73 | -35.14 | -9.55 |
| Net income 1 | -117.8 | -79.98 | -78.75 | -37.73 | -35.14 | -9.55 |
| Net margin | - | - | -19,786.68% | -1,291.24% | -702,800% | - |
| EPS 2 | -10.50 | -5.700 | -5.550 | -2.550 | -2.200 | -0.6000 |
| Free Cash Flow | - | -66.79 | -64.79 | - | - | - |
| FCF margin | - | - | -16,279.15% | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 3/2/20 | 2/25/21 | 3/30/22 | 3/7/23 | 4/1/24 | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 0.398 | - | - | - | 2.911 | 0.011 | - | 0.004 | - | 0.001 |
| EBITDA | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | -22.3 | -10.31 | -9.085 | -9.233 | -8.264 | -8.521 | -9.672 | -7.982 | -8.664 | -7.949 |
| Operating Margin | -5,602.01% | - | - | - | -283.89% | -77,463.64% | - | -199,550% | - | -794,900% |
| Earnings before Tax (EBT) 1 | -22.73 | -11.79 | -9.788 | -9.932 | -8.851 | -9.159 | -10.05 | -8.773 | -8.476 | -7.843 |
| Net income 1 | -22.73 | -11.79 | -9.788 | -9.932 | -8.851 | -9.159 | -10.05 | -8.773 | -8.476 | -7.843 |
| Net margin | -5,711.81% | - | - | - | -304.05% | -83,263.64% | - | -219,325% | - | -784,300% |
| EPS 2 | -1.650 | -0.7500 | -0.7500 | -0.7500 | -0.6000 | -0.6000 | -0.6000 | -0.6000 | -0.6000 | -2.090 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 11/8/21 | 3/30/22 | 5/16/22 | 8/15/22 | 11/14/22 | 3/7/23 | 5/10/23 | 8/14/23 | 11/14/23 | 4/1/24 |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - |
| Net Cash position | - | 115 | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow | - | -66.8 | -64.8 | - | - | - |
| ROE (net income / shareholders' equity) | - | -73% | - | - | - | - |
| ROA (Net income/ Total Assets) | - | -62.6% | - | - | - | - |
| Assets 1 | - | 127.7 | - | - | - | - |
| Book Value Per Share | - | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - | - |
| Capex | - | 9.78 | - | - | - | - |
| Capex / Sales | - | - | - | - | - | - |
| Announcement Date | 3/2/20 | 2/25/21 | 3/30/22 | 3/7/23 | 4/1/24 | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
1.32
Average target price
-
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +24.47% | 21.14M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.74B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- TCRT Stock
- Financials Alaunos Therapeutics, Inc.
